
Acorda Therapeutics ACOR
Quartalsbericht 2024-Q1
hinzugefügt 14.05.2024
Acorda Therapeutics Betriebsaufwand 2011-2026 | ACOR
Betriebsaufwand Jährlich Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 206 M | 279 M | 279 M | 348 M | 439 M | 355 M | 275 M | 239 M | 223 M | 191 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 439 M | 191 M | 283 M |
Betriebsaufwand Vierteljährlich Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141 M | 141 M | 133 M | - | 123 M | 108 M | 101 M | - | 85.1 M | 86.2 M | 77.1 M | - | 73.5 M | 78.3 M | 74.4 M | - | 67.1 M | 70.6 M | 62.4 M | - | 72.4 M | 64.4 M | 60.8 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 141 M | 60.8 M | 90 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
512 M | $ 97.54 | -5.71 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Burford Capital Limited
BUR
|
106 M | $ 5.2 | 5.69 % | $ 820 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Cerus Corporation
CERS
|
149 M | $ 2.72 | 33.99 % | $ 518 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 21.95 | -2.23 % | $ 3.64 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Cardiff Oncology
CRDF
|
49.6 M | $ 1.71 | -1.16 % | $ 114 M | ||
|
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Editas Medicine
EDIT
|
201 M | $ 2.9 | -3.33 % | $ 257 M | ||
|
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | ||
|
Edesa Biotech
EDSA
|
6.71 M | $ 17.59 | -3.75 % | $ 56.2 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.93 | -8.15 % | $ 4.82 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
62.1 M | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
34.4 M | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Evogene Ltd.
EVGN
|
13.8 M | $ 0.81 | 3.33 % | $ 27.9 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M |